ArticleClinical and translational science2023

First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteers.

Fei Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.